Lanadelumab-flyo

Brand names: Takhzyro · Active ingredient: Lanadelumab

In short: TAKHZYRO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.

Forms & strengthsInjection: Sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution available as follows: 150 mg/mL solution in a single-dose prefilled syringe 300 mg/2 mL (150 mg/mL) solution in a single-dose prefilled syringe
LabelTakeda Pharmaceuticals America, Inc.
Label updatedSep 21, 2026

What is Lanadelumab-flyo used for?

TAKHZYRO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.

Lanadelumab-flyo dosage

The recommended starting dosage in adult and pediatric patients 12 years of age and older is 300 mg administered subcutaneously every 2 weeks (q2wks). A dosing interval of 300 mg every 4 weeks (q4wks) is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.

Pediatric Patients 6 Years to Less Than 12 Years of Age

The recommended starting dosage in pediatric patients 6 years to less than 12 years of age is 150 mg administered subcutaneously every 2 weeks (q2wks). A dosing interval of 150 mg every 4 weeks (q4wks) may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.

Pediatric Patients 2 Years to Less Than 6 Years of Age

The recommended dosage in pediatric patients 2 years to less than 6 years of age is 150 mg administered subcutaneously every 4 weeks (q4wks).

TAKHZYRO is administered subcutaneously only.

TAKHZYRO is intended for administration by a healthcare provider, patient or caregiver.

The patient or caregiver should be trained in subcutaneous injection technique by a healthcare professional.

Adult and pediatric patients 12 years of age and older: TAKHZYRO may be administered by the patient or caregiver.

Pediatric patients 2 years to less than 12 years of age: TAKHZYRO should be administered by a healthcare provider or caregiver.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use TAKHZYRO if the solution appears discolored or contains visible particles. TAKHZYRO is a clear to slightly opalescent, colorless to slightly yellow solution.

Administration Instructions for Single-Dose Prefilled Syringes

Instruct patients and/or caregivers on proper use of the TAKHZYRO prefilled syringe and assess that they are well trained in subcutaneous injection technique prior to administration by patient and/or caregiver.

Avoid vigorous agitation of the prefilled syringe.

Take the TAKHZYRO prefilled syringe out of the refrigerator 15 minutes before injecting to allow it to equilibrate to room temperature.

Using aseptic technique, inject TAKHZYRO subcutaneously into the abdomen, thigh, or upper arm.

Discard any unused portion of drug remaining in the prefilled syringe.

For detailed instructions on the preparation and administration of TAKHZYRO see Instructions for Use for either single-dose 1 mL prefilled syringe or single-dose 2 mL prefilled syringe.

How to take Lanadelumab-flyo — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Hypersensitivity

Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions .

Self-Administration:

Ensure that the patient or caregiver receives clear instructions and training on subcutaneous administration and has demonstrated the ability to perform a subcutaneous injection.

Instruct patients or caregivers in the technique of proper syringe and needle disposal, and advise them not to reuse these items. Instruct patients or caregivers to dispose needles and syringes in a puncture-resistant container.

Warnings & precautions

Do not take this medicine if: None.

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Lanadelumab-flyo side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adult and Pediatric Patients 12 Years of Age and Older

The safety of TAKHZYRO is primarily based on a 26-week, randomized, double-blind, parallel-group and placebo-controlled study (Trial 1) in 125 patients with Type I or II HAE. Eligible patients were also able to participate in an open-label extension study (Trial 2) up to 130 weeks. In Trial 1, a total of 84 patients with HAE aged 12 years and older received at least one dose of TAKHZYRO. Overall, 70% of patients were female and 90% of patients were Caucasian with a mean age of 41 years. The proportion of patients who discontinued study drug prematurely due to adverse events was 1.2% for TAKHZYRO-treated patients and 4.9% for placebo-treated patients. No deaths occurred in the trial.

The safety profile of TAKHZYRO was generally similar across all subgroups of patients, including analysis by age, sex, and geographic region.

Table 1 shows adverse reactions occurring in ≥10% of patients in any TAKHZYRO treatment group that also occurred at a higher rate than in the placebo treatment group in Trial 1. …

Drug interactions

No dedicated drug interaction studies have been conducted .

Coagulation tests

TAKHZYRO can increase activated partial thromboplastin time (aPTT) due to an interaction of TAKHZYRO with the aPTT assay. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system. Inhibition of plasma kallikrein by TAKHZYRO can increase aPTT in this assay. In Trial 1, prolongation of aPTT (>1× ULN) was observed at one or more time points in 3, 9, and 11 patients treated with TAKHZYRO 150 mg every 4 weeks (q4wks), 300 mg every 4 weeks (q4wks), and 300 mg every 2 weeks (q2wks), respectively, compared to 5 placebo-treated patients. Only one patient in the 300 mg every 2 weeks (q2wks) treatment group experienced transient aPTT prolongation ≥1.5x ULN which was confounded by ongoing heparin therapy. None of the increases in aPTT in patients treated with TAKHZYRO were associated with abnormal bleeding adverse events. There were no differences in INR values between treatment groups.

About this medicine

Lanadelumab-flyo, a plasma kallikrein inhibitor, is a non-plasma derived, recombinant, fully human, monoclonal antibody (IgG1/κ-light chain) produced in Chinese Hamster Ovary (CHO) cells. Based on the amino acid sequence, the molecular weight of the non-glycosylated lanadelumab-flyo is 146 kDa. The calculated molecular mass of the fully reduced light chain is 23 kDa. The calculated molecular mass of the fully reduced and non-glycosylated heavy chain is 49 kDa.

TAKHZYRO (lanadelumab-flyo) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous use.

Each mL of ready-to-use TAKHZYRO solution contains 150 mg of lanadelumab-flyo, citric acid monohydrate (4.1 mg), L-histidine (7.8 mg), polysorbate 80 (0.1 mg), sodium chloride (5.3 mg), sodium phosphate dibasic dihydrate (5.3 mg), and Water for Injection, USP. The solution has a pH of approximately 6.0.

How it works: Lanadelumab-flyo is a fully human monoclonal antibody (IgG1/κ-light chain) that binds plasma kallikrein and inhibits its proteolytic activity. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8. Read the full official label on DailyMed.